Study To Know The Rifaximin Efficacy In Hepatic Encephalopathy Prevention In Cirrhosis Of Liver

Dr.Madiha Waseem Dr.Fatima Munir
2018 Zenodo  
Objective: To evaluate the safety and efficacy of Rifaximin in patients with liver cirrhosis to prevent hepatic encephalopathy recurrence according to lactulose alone. Study design: Randomized controlled trial. Location and duration: In the Gastroenterology department of Bahawal Victoria Hospital, Bahawalpur for the Period of one year from May 2016 to May 2017. Methodology: We had hepatic encephalopathy reports for approximately 4 weeks of liver cirrhosis to randomly receive selected rifaximin.
more » ... selected rifaximin. 550 mg twice daily dose in 196 patients received (99 patient) or only lactulose (97 patients). They asked or found patients to take oral medication twice a day for 6 months until they experienced HE's recurrence. RESULTS: Hepatic encephalopathy reduces recurrence over a period of significant six months, when compared with lactulose alone. Hepatic encephalopathy was suddenly present in 19 (19.19%) of the patients taking rifaximin, compared with 49 (50.51%) patients in the lactulose group. Hepatic encephalopathy was admitted in 12.6% (8) of the patients in the rifaximin group and 23.8% (15) in the total lactulose group, compared to the disease. 79 patients (79.79%) in the rifaximin group and 48 patients (49.48%) in the lactulose group had hepatic encephalopathy during the study period. In the majority of patients with advanced HE, 21-25 was the MELD score was in both groups. In both groups Death rate and morbidity rate was same. Conclusion: Treatment with rifaximin at a 6-month period was more effective than lactulose alone in maintaining hepatic encephalopathy remission. In our study, rifaximin reduced hospitalization frequency significantly in patients with hepatic encephalopathy. Key words: Hepatic encephalopathy, Rifaximin, Liver cirrhosis.
doi:10.5281/zenodo.1298657 fatcat:dwrfy3pv7na2boqqr4sgwsnhsy